Revelation Biosciences reports Q4 and FY2025 results; cash $10.7M, net loss $8.9M

REVELATION BIOSCIENCES, INC.

2025-FY EPS reported -$23.95

Cash and cash equivalents $10.7M as of Dec 31, 2025 vs $6.5M in 2024; net proceeds of $6.7M from warrant inducement in January 2026
Net loss for FY2025 was $8.9 million ($23.95 per share) vs $15.0 million ($1,052.16 per share) in FY2024
Announced positive results from PRIME clinical study in late-stage chronic kidney disease patients
Reached agreement with FDA on a single adaptive Phase 2/3 study for Gemini to treat acute kidney injury
Clinical data on Gemini for AKI and CKD to be presented at International Conference on Advances in Critical Care Nephrology (March 29-April 1, 2026)

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.